Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
|Articles|April 9, 2010
Two Long-Standing Independent IRBs Met Terms to Merge
Advertisement
While the individual boards of each company will continue their review of existing projects respectively, all new submissions of business will be accepted and managed by Ethical and Independent Review Services, LLC (E&I). E&I will offer review of research by an AAHRPP accredited board in California. A second board in the Midwest anticipates receipt of accreditation in the coming months.
Services offered through E&I will include reviews of both private and federally funded research, training and consulting services, and the development of more specialized review boards. Both companies are excited by this opportunity to provide a larger spectrum of review services and a greater base of experience from which they can support their human subject protection program.
Both companies have experience in the review of late-stage, multi-center trials. While IRC specializes in medical devices and federally funded studies, ERC has developed processes specializing in efficient turn-around of large, late-stage multi-center trials.
An E&I Review Services website, with automated forms, will be available at completion of merger, anticipated in coming weeks.
Advertisement
Related to this article
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong.
CRIO’s Mike Wenger, speaker at this year's SCRS summit, maps how sites are actually deploying AI post-pilot stage.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5